Öcal Serkan, Harmancı Özgür, Korkmaz Murat, Ensaroğlu Fatih, Çolak Turan, Selçuk Haldun, Moray Gökhan, Haberal Mehmet
From the Department of Gastroenterology and Hepatology, Başkent University, Faculty of Medicine, Ankara, Turkey.
Exp Clin Transplant. 2015 Apr;13 Suppl 1:193-6.
Chronic hepatitis C virus infection compromises hemodialysis patients and increases liver-related mortality. Interferon treatment is associated with improved sustained virological response rates and increased risk of graft loss after kidney transplant. This may be related to the development of antihuman leukocyte antigen antibodies, which may be a surrogate marker of potent immune response. We evaluated panel reactive antibody 1 and 2 levels for prediction of sustained viral response in patients with kidney transplant.
In this retrospective cohort study, we reviewed data from hepatitis C virusinfected hemodialysis patients who received interferon treatment before kidney transplant. Panel reactive antibody > 20% was considered positive. Sustained viral response rates for interferon treatment were obtained and compared with panel reactive antibody 1 and 2 values.
There were 40 patients (16 female and 24 male patients; mean age, 41.5 y; range, 18-65 y). Sustained viral response rate was 18/40 (45%). Panel reactive antibody 1 was negative in 31 patients and positive in 9 patients. Sustained viral response ratio was not correlated with panel reactive antibody 1 positivity. Panel reactive antibody 2 was negative in 31 patients (sustained viral response: present, 11 patients; absent, 20 patients) and positive in 9 patients (sustained viral response: present, 7 patients; absent, 2 patients). Sustained viral response ratio was significantly correlated with panel reactive antibody 2 positivity.
We showed a correlation between panel reactive antibody 2 positivity and sustained viral response rates that may be a predictive tool for hepatitis C virus treatment response. In patients with other complications that compromise hepatitis C virus treatment, panel reactive antibody 2 may be a surrogate marker for sustained viral response prediction. The induction of cellular immunity may cause clearance of hepatitis C virus infection and formation of high panel reactive antibody 2 levels.
慢性丙型肝炎病毒感染会影响血液透析患者，并增加肝脏相关死亡率。干扰素治疗与持续病毒学应答率的提高以及肾移植后移植物丢失风险的增加有关。这可能与抗人类白细胞抗原抗体的产生有关，该抗体可能是强效免疫反应的替代标志物。我们评估了群体反应性抗体1和2水平，以预测肾移植患者的持续病毒应答。
在这项回顾性队列研究中，我们回顾了肾移植前接受干扰素治疗的丙型肝炎病毒感染血液透析患者的数据。群体反应性抗体>20%被视为阳性。获得干扰素治疗的持续病毒应答率，并与群体反应性抗体1和2值进行比较。
共有40例患者（16例女性和24例男性患者；平均年龄41.5岁；范围18 - 65岁）。持续病毒应答率为18/40（45%）。31例患者群体反应性抗体1为阴性，9例为阳性。持续病毒应答率与群体反应性抗体1阳性无关。31例患者群体反应性抗体2为阴性（持续病毒应答：存在，11例；不存在，20例），9例为阳性（持续病毒应答：存在，7例；不存在，2例）。持续病毒应答率与群体反应性抗体2阳性显著相关。
我们发现群体反应性抗体2阳性与持续病毒应答率之间存在相关性，这可能是丙型肝炎病毒治疗反应的预测工具。在有其他并发症影响丙型肝炎病毒治疗的患者中，群体反应性抗体2可能是持续病毒应答预测的替代标志物。细胞免疫的诱导可能导致丙型肝炎病毒感染的清除和高群体反应性抗体2水平的形成。
